TSE:MDNA Medicenna Therapeutics (MDNA) Stock Price, News & Analysis → The AI Bottleneck No One is Talking About (From The Bull Report) (Ad) Free MDNA Stock Alerts C$1.53 -0.03 (-1.92%) (As of 03/18/2024 ET) Add Compare Share Share Today's RangeC$1.53▼C$1.7350-Day RangeC$0.40▼C$1.5752-Week RangeC$0.22▼C$1.75Volume113,434 shsAverage Volume90,523 shsMarket CapitalizationC$106.55 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades Get Medicenna Therapeutics alerts: Email Address Ad The Bull ReportThe AI Bottleneck No One is Talking AboutRenewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.Click here to see who's preparing to meet these needs About Medicenna Therapeutics Stock (TSE:MDNA)Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.Read More MDNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDNA Stock News HeadlinesMarch 6, 2024 | finance.yahoo.comMedicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual MeetingFebruary 13, 2024 | finance.yahoo.comMedicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid TumorsMarch 19, 2024 | Behind the Markets (Ad)BlackRock Bets Big on Tiny BiotechAn undervalued biotech firm is on the verge of a major discovery - That has the potential to treat Alzheimer's, Parkinson's and Dementia. BlackRock is so confident in this firm, they've invested $298 million.January 9, 2024 | finanznachrichten.deMedicenna Therapeutics Corp.: Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with PembrolizumabJanuary 9, 2024 | finance.yahoo.comMedicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with PembrolizumabNovember 20, 2023 | finance.yahoo.comAll You Need to Know About Medicenna Therapeutics Corp. (MDNAF) Rating Upgrade to BuyNovember 14, 2023 | finanznachrichten.deMedicenna Therapeutics Corp.: Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational HighlightsNovember 9, 2023 | finance.yahoo.comMedicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual MeetingMarch 19, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… October 24, 2023 | tmcnet.comMedicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer's (SITC)October 24, 2023 | finance.yahoo.comMedicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)October 10, 2023 | finanznachrichten.deMedicenna Therapeutics Corp.: Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical OfficerOctober 5, 2023 | nasdaq.comMedicenna Therapeutics (MDNA) Price Target Increased by 34.63% to 3.93October 3, 2023 | finance.yahoo.comMedicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and ImmunotherapySeptember 29, 2023 | finanznachrichten.deMedicenna Therapeutics Corp.: Medicenna Announces Results of Annual and Special Meeting of ShareholdersSeptember 28, 2023 | finance.yahoo.comMedicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and ImmunotherapySeptember 26, 2023 | finance.yahoo.comIs Medicenna Therapeutics (TSE:MDNA) In A Good Position To Invest In Growth?September 6, 2023 | finance.yahoo.comMedicenna to Participate at The H.C. Wainwright 25th Annual Global Investment ConferenceAugust 28, 2023 | msn.comMedicenna Therapeutics gets new CFOAugust 28, 2023 | finance.yahoo.comMedicenna Announces the Appointment of Jeff Caravella as Chief Financial OfficerAugust 24, 2023 | theglobeandmail.comClosing Bell: Medicenna Therapeutics Corp up on Wednesday (MDNA)August 13, 2023 | markets.businessinsider.comBloom Burton Thinks Medicenna Therapeutics Corp’s Stock is Going to RecoverAugust 9, 2023 | finance.yahoo.comMedicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY StudyAugust 2, 2023 | msn.comMedicenna Therapeutics (MDNA) Price Target Increased by 5.55% to 3.54June 28, 2023 | benzinga.comHC Wainwright & Co. Reiterates Buy on Medicenna Therapeutics, Maintains $2.5 Price TargetJune 28, 2023 | markets.businessinsider.comH.C. Wainwright Maintains Their Buy Rating on Medicenna Therapeutics Corp (MDNA)April 19, 2023 | theglobeandmail.comClosing Bell: Medicenna Therapeutics Corp up on Tuesday (MDNA)See More Headlines Receive MDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:MDNA CUSIPN/A CIKN/A Webwww.medicenna.com Phone+1-403-6807898FaxN/AEmployees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-15,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-59.47% Return on Assets-34.57% Debt Debt-to-Equity Ratio0.06 Current Ratio5.00 Quick Ratio4.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$1.37 per share Price / Cash Flow1.15 Book ValueC$0.27 per share Price / Book5.81Miscellaneous Outstanding Shares69,640,000Free FloatN/AMarket CapC$109.33 million OptionableNot Optionable Beta1.16 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Fahar Merchant Ph.D. (Age 67)Founder, Chairman, President & CEO Comp: $454.37kMs. Rosemina Merchant B.Sc. (Age 67)M.E.Sc, Founder & Chief Development Officer Comp: $364.46kDr. Humphrey A. R. Gardner FCAPM.D., Chief Medical OfficerDr. Samuel R. Denmeade M.D.Scientific AdvisorKey CompetitorsIntelGenx TechnologiesCVE:IGXTheratechnologiesTSE:THNovoheartCVE:NVH138267 (COM.TO)TSE:COMScythian BiosciencesCVE:SCYBView All Competitors MDNA Stock Analysis - Frequently Asked Questions How have MDNA shares performed in 2024? Medicenna Therapeutics' stock was trading at C$0.42 at the start of the year. Since then, MDNA shares have increased by 264.3% and is now trading at C$1.53. View the best growth stocks for 2024 here. What other stocks do shareholders of Medicenna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medicenna Therapeutics investors own include OPKO Health (OPK), AbbVie (ABBV), Livongo Health (LVGO), Aptose Biosciences (APTO), Birchcliff Energy (BIR), CVS Health (CVS), Freehold Royalties (FRU), Fastly (FSLY) and Inovio Pharmaceuticals (INO). How do I buy shares of Medicenna Therapeutics? Shares of MDNA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:MDNA) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceDid you make $29,000 two days with AI options trades?Prosper Trading AcademyThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicenna Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.